Thrivent Financial For Lutherans Mersana Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $8,774 - $27,207	-2,849 Reduced 4.68%	58,073 $191,000
Q4 2022 Feb 08, 2023	BUY	$5.65 - $7.86 $344,209 - $478,846	60,922 New	60,922 $357,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $498,126 - $862,854	-32,536 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $155,887 - $255,400	9,257 Added 39.77%	32,536 $865,000
Q3 2020 Nov 10, 2020	SELL	$16.2 - $25.7 $154,353 - $244,869	-9,528 Reduced 29.04%	23,279 $433,000
Q2 2020 Aug 12, 2020	BUY	$5.24 - $23.4 $48,506 - $216,613	9,257 Added 39.31%	32,807 $768,000
Q1 2020 May 15, 2020	BUY	$4.41 - $9.28 $103,855 - $218,543	23,550 New	23,550 $137,000

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.